Securing the Conditions to Secure Our Meds
The AAM’s Dan Leonard highlights the savings impact that generic and biosimilar have on US healthcare today and introduces the ‘Secure Our Meds’…
Tagged with Opinion
IFPMA’s Thomas Cueni on why “#TeamVaccines is all of…
Thomas Cueni of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) highlights the incredible progress of COVID-19…
After Brexit: Focus on the New Pharmaceutical Strategy for Europe
Writing in the February edition of DIA’s Global Forum magazine, Thomas Kühler of Sanofi R&D looks at the future of European pharma post-Brexit,…
Curing the Incurable: Cell & Gene Therapy and A New Age for…
Bayer’s Michael Levy casts his eye over the implications of the advent of cell and gene therapies on pharmacovigilance and patient safety. Levy…
China’s National Reimbursement Drug List (NRDL) 2020: What…
Eric Bouteiller examines the most recent update to China’s National Reimbursement Drug List, the positive impact that a de facto annual review has…
Navigating the Increasingly Stormy Waters of US Market Access
Certara's Ulrich Neumann examines some of the major US market access trends of the past few years, including the innovative financing models required…
Embryonic Gene Editing: How Far is Too Far to Find a Treatment…
Rare disease patient advocate Monica Weldon outlines some of the ethical conundrums around embryonic gene editing. With CRISPR technology again in the…
Securing Trust in the COVID-19 Supply Chain: From Development…
Scientists have come together in an unparalleled worldwide collaboration and sharing of data to advance a COVID-19 vaccine.[1] As rollouts become…
5 Trends for Life Science Companies to Watch in 2021
After a transformative 2020, Shawview Consulting’s Brendan Shaw looks into his crystal ball and makes five predictions (plus one) on the key trends…
Can Sweden take the lead in Precision Medicine?
Anders Blanck of Lif, the trade association for the research-based Swedish pharmaceutical industry, outlines the steps already being put in place for…
10 Key Insights from PharmaBoardroom Contributors in 2020
Although the COVID-19 pandemic and the subsequent rush to develop diagnostics, therapeutics, and vaccines dominated the global headlines in 2020,…
The Value Proposition of Generics & Biosimilars in the USA
AAM President Dan Leonard highlights the findings of the association’s most recent report and re-states the value proposition of generic and…
